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Gerard SocieAcute graft-versus-host disease (aGVHD) is a com-
mon immunologic complicationwhichoccurs in 40%to
50%of the recipients of allogeneic stem cell transplanta-
tion (SCT).The immunologic events leading to injuryof
the target organs—skin, liver, and gut—involve activa-
tion and clonal expansion of the donor’s effector T cells
in response to the recipient’s disparate major or minor
histocompatibility antigens. The morbidity and mortal-
ity of this complication correlateswith the severity of the
organ involvement. The main treatment strategy for
aGVHD routinely entails the intensification of immu-
nosuppression which often leads to serious infectious
complications.Death in patientswith aGVHDisusually
due to organ failure or overwhelming infections. Thus,
major research efforts in allogeneic bone marrow trans-
plantation over the past 2 decades have focused on the
prevention of GVHD, mainly with pharmacologic im-
munosuppressive agents. Since 1985, the combination
of cyclosporine (CSP) and short-course methotrexate
(MTX) has been studied extensively for the prevention
of aGVHD and compared to single agents such as
CSP or MTX in randomized trials. This combination
has been adopted as standard care in most centers [1].
Subsequently, the combination of tacrolimus
(TAC) and MTX has been shown to be at least as
effective as CSP and MTX [2]. For patients receiving
a nonmyeloablative preparative regimen, GVHD pro-
phylaxis is frequently based on a calcineurin inhibitor
(CNI) and mycophenolate mofetil (MMF). Although
both MTX and MMF are usually given at fixed doses,
CNI dosing is typically adjusted both to avoid toxic-
ities, especially renal, and to maintain whole-blood
concentrations within a therapeutic range.
In this issue, the Seattle group reports on a large co-
hort of patientswith the aim todeterminewhetherCNI
blood concentrations within the first month after
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analyzed data from more than 1000 patients with
hematological malignancies who had SCT from
HLA-matched related or unrelated donors over the
last 10-years [3]. After myeloablative HCT, higher
CNI concentrations were not associated with lower
risks of acute or chronic GVHD. However, after non-
myeloablative SCT (in over 400 patients), higher CSP
concentrations were associated with decreased risks of
grade II to IV and III to IV aGVHD, nonrelapse, and
overall mortality. CSP concentrations were not associ-
ated with risks of chronic GVHD and recurrent
malignancy after nonmyeloablative HCT. Among pa-
tients givenTAC after nonmyeloablativeHCT, a simi-
lar trend of CNI-associated GVHD protection was
observed. The authors conclude that higher CSP
concentrations relatively early after nonmyeloablative
HCTconfer protection against aGVHDthat translates
into reduced risks of nonrelapse and overall mortality.
The authors have to be congratulated for this ex-
tremely useful study based on huge number of patients
(and dosage). However, some points should be dis-
cussed. As stated correctly by the authors, a large
prospective trial showed only a trend toward an associ-
ation between low CSP concentrations and increased
risk of GVHD, whereas no correlation was found be-
tween TAC concentrations and risk of GVHD [4].
Data presented by the authors are retrospective and
show evolution in the use of CSP and TAC with
decreased use of CSP with year of transplant both
after myeloablative and nonmyeloablative condition-
ing (Table 1 in the article). Furthermore the signifi-
cance of lower dose of CSP is mainly based on the
lower quartile. Finally, in patients given TAC, higher
week 2 mean levels were correlated only with the risk
of grade 3 to 4 aGVHD, whereas no correlation was
observed with grade 2 to 4 aGVHD. Also there is no
clear explanation why the benefit of adequate CNI
dosage should be restricted to SCT after nonmyeloa-
blative conditioning. Finally, it should be stressed
that the benefit associated with higher CNI concentra-
tions after nonmyeloablative SCT might be related to
the use of MMF instead of MTX (as correctly
discussed by the authors) and the reader reminded
that formal comparison of MTX and MMF in associ-
ation with a CNI in the setting of a large prospective
randomized trial has never been done.331
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(Still Unanswered) Question
Robert J. SoifferA 41 year old man presents to you with pancyto-
penia. He is asymptomatic except for mild fatigue.
Liver, pulmonary, and kidney function are normal.
Bone marrow biopsy is normocellular with multiline-
age dysplasia. Myeloblasts represent 15% of the mar-
row cellularity. There are no circulating peripheral
blasts. Chromosome analysis reveals monosomy 7 in
13 of 20 metaphases. The patient’s brother is healthy
and HLA-identical. Based on the patient’s diagnosis
of myelodysplastic syndrome, high international
prognostic scoring system, lack of comorbidities,
and available HLA-identical sibling donor, you rec-
ommend allogeneic hematopoietic cell transplanta-
tion (HCT) [1].
Your fellow asks you, ‘‘Do you think we should
treat the patient first in order to decrease the number
of marrow blasts before transplantation? Will that
lead to lower relapse rates and superior long term sur-
vival? Should we use a hypomethylating agent or do
you think full leukemia induction with cytosine arabi-
noside and anthracycline is best?’’ You pause, stroke
your chin, and prepare to educate your knowledge
hungry fellow. But the best you can do is reply, ‘‘I
don’t know.’’
Although allogeneic HCT has been performed
for myelodysplasia for over 25 years, there remains
no clear consensus on the advisability of cyto-reductive therapy before transplantation. Unfortu-
nately, there are no randomized trials to help guide
practitioners and retrospective studies are generally
subject to selection bias. Nonetheless, Scott et al.
[2] reported in Biology of Blood and Marrow Transplan-
tation in 2005 a series of 125 patients with advanced
myelodysplastic syndrome (MDS) treated in Seattle
with myeloablative transplantation. In that retrospec-
tive series, 33 patients received induction chemother-
apy whereas 92 patients were taken directly to
transplantation. No significant difference in relapse-
free or overall survival was noted in patients who
had received pretransplant chemotherapy compared
with those who were chemotherapy na€ıve. This of
course does not even account for those patients
with advanced MDS who received induction chemo-
therapy and never received a transplantation either
because of morbidity from treatment or lack of re-
sponse to the induction chemotherapy. Nakia et al.
[3] reported a similar experience from Japan, again
in ablative transplantation recipients. The impact of
induction chemotherapy may be different in patients
receiving nonmyeloablative conditioning as the expe-
rience reported by Warlick et al. [4] in Minnesota
suggested a trend for better outcome in nonmyeloa-
blative recipients who had received pretransplant
treatment.
In this issue of the Biology of Blood and Marrow
Transplantation, Saure et al. [5] present a novel strategy
for patients with advanced MDS. They treated 30
patients with fludarabine, amsacrine, and cytosine
arabinoside followed 2 to 3 days later by high dose
melphalan-based conditioning and allogeneic hemato-
poietic stem cell infusion. Thus, induction chemother-
apywas actually combinedwith allogeneicHCT rather
than delivered as a 2-step process. They report an en-
couraging 63% 2-year disease-free survival estimate.
